Advanced search
Publication Cover
Nordic Journal of Psychiatry Volume 61, 2007 - Issue 2
Submit an article Journal homepage
250
Views
14
CrossRef citations to date
0
Altmetric
Original

A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

Jan Sørensen CAST – Centre for Applied Health Services Research and Technology Assessment, University of Southern Denmark, J. B. Winsløws Vej 9B, DK-5000, Odense C, DenmarkCorrespondence[email protected]
, M.Sc.(health econ.),
Kurt B. Stage Department of Psychiatry, Odense University Hospital, DK-5000, Odense C, Denmark
, Ph.D. , M.D.,
Niels Damsbo Institute of Public Health – General Practice, University of Southern Denmark, J. B. Winsløws Vej 9A, DK-5000, Odense C, Denmark
, M.D.,
Agathe Le Lay H. Lundbeck A/S, Economics and Pricing Division, International Health Economics and Epidemiology Department, Paris, France, (at the time of the analyses)
, M.Sc. &
Michiel E. Hemels H. Lundbeck A/S, Economics and Pricing Division, International Health Economics and Epidemiology Department, Paris, France, (at the time of the analyses)
, Drs. , MSc
Pages 100-108 | Published online: 12 Jul 2009

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Zheng-Yi Zhou, Shawn Sun, Pooja Chopra, Yichen Zhong, Todor Totev & James Signorovitch. (2015) Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. Journal of Medical Economics 18:11, pages 919-929.
Read now
Andrew P. Yu, Jipan Xie, Arielle Bensimon, Kejal Parikh, Eric Q. Wu, Rym Ben-Hamadi, Steven Blum & M. Haim Erder. (2010) Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study. Journal of Medical Economics 13:4, pages 599-609.
Read now
Eric Q. Wu, Rym Ben-Hamadi, Andrew P. Yu, Jackson Tang, M. Haim Erder & Anjana Bose. (2010) Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons. Journal of Medical Economics 13:2, pages 314-323.
Read now
Alan G. Wade, Delphine Saragoussi, Nicolas Despiégel, Clément François, Florent Guelfucci & Mondher Toumi. (2010) Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK. Current Medical Research and Opinion 26:5, pages 1161-1170.
Read now
Feng Xie, Nicolas Despiegel, Natalya Danchenko & Karina Hansen. (2009) Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice 13:1, pages 59-69.
Read now
Cyril Höschl & Jaromír Švestka. (2008) Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics 8:4, pages 537-552.
Read now
Raymond W Lam & Lieven Annemans. (2007) Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, pages 559-576.
Read now

Articles from other publishers (7)

Yong Wang, Yi-hua Shi, Zhen Xu, Huan Fu, Hua Zeng & Guo-qing Zheng. (2019) Efficacy and safety of Chinese herbal medicine for depression: A systematic review and meta-analysis of randomized controlled trials. Journal of Psychiatric Research 117, pages 74-91.
Crossref
Lieven Annemans, Mélanie Brignone, Sylvain Druais, Ann De Pauw, Aline Gauthier & Koen Demyttenaere. (2014) Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium. PharmacoEconomics 32:5, pages 479-493.
Crossref
Mark J.C. Nuijten, Mélanie Brignone, Florence Marteau, Johan A. den Boer & Erik Hoencamp. (2012) Cost-Effectiveness of Escitalopram in Major Depressive Disorder in the Dutch Health Care Setting. Clinical Therapeutics 34:6, pages 1364-1378.
Crossref
Göran Nordström, Natalya Danchenko, Nicolas Despiegel & Florence Marteau. (2012) Cost-Effectiveness Evaluation in Sweden of Escitalopram Compared with Venlafaxine Extended-Release as First-Line Treatment in Major Depressive Disorder. Value in Health 15:2, pages 231-239.
Crossref
Marieke Krol, Jocé Papenburg, Marc Koopmanschap & Werner Brouwer. (2012) Do Productivity Costs Matter?. PharmacoEconomics 29:7, pages 601-619.
Crossref
Karly P. Garnock-Jones & Paul L. McCormack. (2010) Escitalopram. CNS Drugs 24:9, pages 769-796.
Crossref
Brian Leonard & David Taylor. (2010) Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression. Journal of Psychopharmacology 24:8, pages 1143-1152.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.